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Abstract
Background: This randomised controlled trial (RCT) with two parallel arms will evaluate the efficacy of an
internet-delivered six-lesson 10-week cognitive behavioural therapy (iCBT) intervention for posttraumatic stress
disorder (PTSD). It will also investigate the association between changes in PTSD symptoms, intolerance of uncertainty
(IU) and emotion regulation.
Methods/Design: Patients with PTSD will be recruited via the research arm of a not-for-profit clinical and research unit
in Australia and randomised to a treatment group or waitlist control group. The minimum sample size for each group
(alpha 0.05, power 0.80 for a g of 0.47) was identified as 72, but 10 % more will be recruited to hedge against expected
attrition. PTSD diagnosis will be determined using the PTSD module from the Mini International Neuropsychiatric
Interview version 5.0.0. The PTSD Checklist – Civilian version (PCL-C) will be used to measure PTSD symptoms (the
primary outcome measure), with the Intolerance of Uncertainty Scale 12-item version (IUS-12) and the Emotion
Regulation Questionnaire (ERQ) used to measure intolerance of uncertainty and emotion regulation, respectively.
The PCL-C will be administered to the treatment group before each lesson of the PTSD program and at 3-month
follow-up. The IUS-12 and ERQ will be administered before lessons 1 and 4, at post-treatment and at 3-month
follow-up. The waitlist control group will complete these measures at week 1, week 5 and week 11 of the waitlist
period. PTSD program efficacy will be determined using intent-to-treat mixed models. Maintenance of gains will
be assessed at 3-month follow-up. Mediation analyses using PROCESS will be used to examine the association
between change in PTSD symptoms over treatment and change in each of IU and emotion regulation ability in
separate analyses.
Discussion: The current RCT seeks to replicate previous efficacy findings of iCBT for PTSD in a formally assessed
PTSD sample from the general population. Findings may point to future lines of enquiry for the role of IU and
emotion regulation in the mechanism of PTSD symptom change during CBT.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12614001213639, registered 18 November
2014. This trial protocol is written in compliance with the Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines.
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Background
Posttraumatic stress disorder (PTSD) can follow experien-
cing a traumatic event in which the individual experiences
or witnesses severe threat to life or physical safety. It is
characterised by recurrent intrusive thoughts or memories
of the traumatic event, avoidance of trauma reminders,
elevated physiological arousal and negative changes in
thoughts and mood [1]. The lifetime prevalence of PTSD
is approximately 7 % in the general population [2–4]. It
has a chronic course when untreated – up to one third of
those with PTSD remain symptomatic for 30 years [5].
The impact of the disorder on the individual is significant.
Compared to those without the disorder, PTSD is in-
dependently associated with: greater prevalence of
physical health conditions, such as respiratory disease,
cardiovascular disease, cancer and gastrointestinal ill-
nesses [6], but see [7]; increased comorbidity of men-
tal health conditions, such as anxiety disorders and
depression [8]; and increased risk of suicidal behav-
iour [9]. Taken together, these data indicate a signifi-
cant individual impact from the disorder, as well as
societal cost in terms of burden of disease.
Cognitive behavioural therapy (CBT) is the psycho-
logical treatment of choice for PTSD and is recom-
mended by best-practice treatment guidelines e.g. [10, 11].
CBT typically involves confrontation with, and process-
ing of, the trauma memory in a safe, gradual manner;
identification and restructuring of problematic beliefs;
and dearousal skills. There is strong research evidence
for use of these CBT techniques to treat PTSD in terms
of magnitude of symptom reduction from pre-treatment
levels, and diagnostic recovery [12–15]. Despite this
evidence, those with PTSD are an underserviced popu-
lation. The majority of those with PTSD do not seek
treatment and those seeking treatment do so with sig-
nificant delay [16]. Associated treatment barriers include
stigma, cost, geography and insufficient treatment avail-
ability [17]. Indeed, McLean and Foa [17] have noted that
development of effective and efficient delivery systems for
evidence-based PTSD treatments remains a key challenge
in the trauma field.
Attempting to counter these difficulties, recent efforts
have examined internet-based delivery of empirically
supported treatment for PTSD symptomatology. Clinical
research has shown that internet-based delivery of cog-
nitive behavioural therapy (iCBT) has utility for treating
PTSD symptoms to an extent approximately equivalent
to face-to-face treatment [18–21]. These treatments are
typically divided into five to ten lesson modules, deliv-
ered over several weeks, with some form of therapist
support (e.g. email or phone).
Though iCBT appears promising in treating PTSD,
variation in experimental design and course structure
means further clinical trials are warranted. Moreover,
the role of emotion process variables in PTSD response
to iCBT has not been examined. To date, published
studies have either not included a control group e.g.
[21], not formally diagnosed PTSD e.g. [19], been based
on a self-help mode of treatment e.g. [22] or required
significant initial therapist input to provide psychoedu-
cation and explain treatment components to the patient
e.g. [18]. Only two published randomised controlled tri-
als (RCT) to date have examined the efficacy of iCBT for
PTSD in a formally diagnosed PTSD sample from the
general population [20, 23]. However, those studies did
not examine mediators of symptom change. Therefore,
in order to extend and validate iCBT for PTSD, the pro-
posed study will conduct an RCT to examine the clinical
efficacy of this approach and mediators of PTSD symp-
tom change.
Emerging evidence suggests intolerance of uncertainty
(IU) as a transdiagnostic construct central to the expres-
sion of psychopathology [24–26]. IU is the tendency to
respond to uncertainty with a negative emotional and
cognitive set and corresponding avoidance and risk miti-
gation behaviour [27]. Recent research has indicated re-
duction in IU is associated with anxiety and depressive
symptom reduction following psychological treatment
[28]. With respect to PTSD, IU has been positively asso-
ciated with severity of arousal, avoidance and numbing
symptoms [29]. However, the association between PTSD
treatment and variation in IU has not been investigated,
nor has the relationship between change in IU and
PTSD symptoms over treatment. Therefore, the current
study will examine these relationships in PTSD.
Finally, recent work has investigated the role of emo-
tion regulation in PTSD treatment outcome. Emotion
regulation is the ability to actively influence the timing,
experience and expression of emotion. Emotion regula-
tion skills training has been shown to reduce dropout
and enhance outcome from subsequent exposure-based
PTSD treatment [30, 31]. Moreover, exposure-based
treatment for PTSD has been associated with enhance-
ment in emotion regulation [32]. However, it remains
unclear whether emotion regulation before treatment
predicts an individual’s response to treatment. While
Wisco et al. [33] found better pre-treatment emotion
regulation skills were not predictive of enhanced PTSD
treatment outcome, that treatment omitted in vivo ex-
posure and cognitive restructuring, treatment compo-
nents to which emotion regulation may be conceptually
related. The association between emotion regulation
and treatment outcome in an internet-delivered inter-
vention for PTSD comprising written exposure, in vivo
exposure and cognitive restructuring has not been in-
vestigated. As such, this study seeks to examine the role
of emotion regulation in PTSD symptom response to
this treatment approach.
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Objectives
The current Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT)-compliant [34]
protocol outlines the methodology of a CONSORT-
compliant [35] RCT, the primary objective of which is
to establish the efficacy of the iCBT program for PTSD.
Secondary objectives are to examine change in IU and
emotion regulation ability following the iCBT program
and the association between change in each of these
constructs and PTSD symptom change following the
PTSD program.
The proposed iCBT program aims to reduce psycho-
logical distress and PTSD symptoms in those with
PTSD. It comprises psychoeducation about the trauma
reaction and how it is maintained after the event by par-
ticular patterns of thinking, feeling and behaving. Dear-
ousal skills are taught and practiced. Participants are
taught ways to identify and change unhelpful thoughts
about the trauma. They will be habituated to their chal-
lenging trauma memories using a series of brief struc-
tured writing assignments and taught graded exposure
methods to re-enter feared situations. Finally, relapse
prevention will cover continued skills practice and in-
struction on independent management of potential fu-
ture setbacks. These elements have been incorporated
into standard CBT-based treatment for PTSD both in
internet and face-to-face formats [12, 18–21, 36–38],
but have been adapted for the proposed internet treat-
ment program.
Hypotheses are as follows: (1) patients receiving iCBT
for PTSD will show greater mean symptom reduction on
a standardised PTSD measure than a waitlist control
group during treatment and at the end of treatment (the
primary endpoint), with preserved symptom reduction
at 3-month follow-up; (2) IU will be less at post-
treatment than pre-treatment; (3) reduction in IU over
treatment will be associated with reduction in PTSD se-
verity; (4) emotion regulation will be greater at post-
treatment than pre-treatment; and (5) increased emotion
regulation after treatment will be associated with re-
duced PTSD severity after treatment.
Methods/Design
Study setting
The Clinical Research Unit for Anxiety and Depression
(CRUfAD) is a non-profit joint initiative of St. Vincent’s
Hospital and the University of New South Wales, School
of Psychiatry in Sydney, Australia. CRUfAD specialises
in the development, evaluation, and dissemination of
evidence-based CBT programs via the internet. This RCT
will be conducted within the Virtual Clinic, CRUfAD’s
clinical research arm (www.virtualclinic.org.au). The mode
of internet recruitment and delivery enables potential
participants from all Australian states to apply for enrol-
ment in the current trial.
Participants and recruitment
Participants will be recruited through flyers, paid print
and internet advertising. Applicants will first complete
online screening questionnaires about symptoms and
demographic details (see Fig. 1 for a participant flow
chart). Inclusion criteria are as follows: meet diagnostic
criteria for PTSD; computer, internet and printer access;
Australian resident; fluent in written and spoken English;
willing to provide name, phone number and address,
and to provide the name and address of a local general
practitioner. Exclusion criteria are as follows: trauma
occurrence within the past 4 weeks; non-resident of
Australia; less than 18 years of age; currently receiving
treatment for trauma/PTSD; frequent suicidal ideation
(indicated by a score of 3 to item 9 of the Patient Health
Questionnaire 9-item version (PHQ9)); regularly using
illicit drugs or regularly consuming more than three
standard drinks per day; psychotic disorder or taking atyp-
ical antipsychotics or benzodiazepines; if taking medica-
tion for anxiety or depression, has been taking the same
dose for less than 1 month or intending to change the
dose during the course of the program; currently highly
dissociative (indicated by score ≥40 on the Dissociative
Experiences Scale as per Spence et al. [20]); current or
pending medicolegal proceedings associated with the re-
ported trauma; applying for, or receiving, Workers Com-
pensation associated with their trauma or PTSD. Excluded
applicants will receive information on alternative services
and will be encouraged to discuss their symptoms with
their physician. Applicants who pass the screening phase
will be telephoned for a diagnostic interview using the
PTSD module from the Mini International Neuropsychi-
atric Interview version 5.0.0 (MINI) [39] to determine
whether they meet diagnostic criteria for PTSD. All inter-
views will be conducted by a registered Clinical Psych-
ologist (AA) or Clinical Trials Manager (JS) under the
guidance of the Clinical Psychologist and trained in ad-
ministration of the diagnostic interview. Applicants
who satisfy all inclusion criteria will be informed of the
study design and will complete an electronic informed
consent prior to enrolling in the trial. Information from
the diagnostic interview will be used for research pur-
poses only for those participants who provide informed
consent. All participants will be informed in writing
that they may withdraw from the study (i.e. choose to
cease program enrolment or choose for their data to be
excluded from the RCT) at any time without jeopardis-
ing their relationship with St. Vincent’s Hospital or the
University of New South Wales. Further, those partici-
pants randomised to the waitlist control group will be
informed that should they commence a trauma-focused
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intervention outside of the trial, their data will be omit-
ted from the RCT.
Trial design and blinding
The trial is a randomised controlled superiority trial
with two parallel arms using a 1:1 allocation ratio. Par-
ticipants will not be blind to their group allocation.
Follow-up interviews will be conducted by clinicians in-
dependent of the study and therefore blind to group
allocation.
Randomisation
Accepted participants will be randomised based on an
allocation sequence generated by an independent person
not involved in the study via a true randomisation
process (www.random.org). Numbers corresponding to
treatment group (1) or the waitlist control group (2) will
be placed in sealed opaque envelopes bearing the se-
quential order number to ensure participant allocation
based on the pre-determined randomisation sequence. A
member of the research team will open the envelope
after the diagnostic interview.
Primary outcome measures
Administration time points for all instruments are con-
tained in Table 1.
Posttraumatic stress disorder Checklist – Civilian
version (PCL-C) [40]. The PCL-C is a 17-item self-
Fig. 1 Participant flow chart
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report questionnaire providing a continuous measure of
PTSD symptomatology, conforming to Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) diagnostic criteria. Each item reflects a PTSD
symptom and is rated on a 5-point scale for distress
(1 = “Not at all”; 5 = “Extremely”). Items 10, 11 and 16
from the PCL-5 [41] will also be administered, which
assess new diagnostic criteria for PTSD in the fifth
edition of the DSM [DSM-5 1]. This approach was
adopted in favour of sole use of the PCL-5, which
had not been validated at the time of trial design.
This will enable examination of change in the new
PTSD symptoms in DSM-5.
PTSD diagnostic status. Change in PTSD diagnostic
status will be indexed using the MINI PTSD module.
The MINI has sound reliability and validity psycho-
metrics [39].
Secondary outcome measures
Patient Health Questionnaire 9-item scale (PHQ-9)
[42]. The PHQ-9 is a self-report questionnaire corre-
sponding to DSM-IV diagnostic criteria for major de-
pressive disorder. Each item is rated in frequency on a
4-point scale (0 = “Not at all”; 3 = “Nearly every day”).
Total scores range from 0 to 27 with higher scores
reflecting greater symptom severity. The PHQ9 demon-
strates sound psychometric properties and has been
used extensively to measure treatment outcomes during
internet CBT interventions targeting depression and
anxiety [43, 44].
Kessler-10 Psychological Distress Scale (K10) [45].
The K10 consists of 10 items ranked on a 5-point scale
designed to measure non-specific psychological distress.
For the current study, the time frame was modified to
assess psychological distress in the past 2 weeks rather
than in the past 30 days. The K10 possesses strong psy-
chometric properties [45, 46].
Generalised Anxiety Disorder 7-Item Scale (GAD-7)
[47]. The GAD-7 is composed of seven items examining
GAD symptom severity and is based on DSM-IV criteria.
Items are measured on a 4-point scale for frequency
of interference from symptoms over the past 2 weeks
(0 = “Not at all”; 3 = “Nearly every day”). Internal
consistency and test-retest reliability are high [47, 48].
Intolerance of Uncertainty Scale – Short Form
(IUS-12) [49]. The IUS-12 is a psychometrically reliable,
valid measure of intolerance of uncertainty [49]. It con-
tains 12 items, each measured on a 5-point scale from 1
(“Not at all characteristic of me”) to 5 (“Entirely charac-
teristic of me”).
Emotion Regulation Questionnaire (ERQ) [50]. The
ERQ is a 10-item self-report measure of cognitive re-
appraisal and emotional suppression as means of regu-
lating emotion. Items are scored on a 7-point scale to
Table 1 Administration time points for questionnaires used in the RCT
Administration time point




PCL-Cb ♦ ♦ ♦ ♦ ♦
BDI-IIc ♦ ♦ ♦ ♦
PHQ-9 ♦ ♦ ♦ ♦
K10 ♦ ♦ ♦ ♦ ♦
GAD-7 ♦ ♦ ♦ ♦
CEQ ♦ ♦
IUS-12 ♦ ♦ ♦ ♦
ERQ ♦ ♦ ♦ ♦
SUDOR ♦ ♦ ♦ ♦
SAPAS ♦
LEC Life Events Checklist, DES Dissociative Experiences Scale, MINI Mini International Psychiatric Interview, PCL-C PTSD Checklist – Civilian version, BDI-II Beck
Depression Inventory – Second Edition, PHQ-9 Patient Health Questionnaire 9-item version, K10 Kessler Psychological Distress Scale 10-item version, GAD-7 Generalised
Anxiety Disorder 7-Item Scale, CEQ - Credibility and Expectancy/Satisfaction Questionnaire, IUS-12 Intolerance of Uncertainty Scale 12-item version, ERQ Emotion Regula-
tion Questionnaire, SUDOR Service Utilisation and Days Out of Role Questionnaire, SAPAS Standardised Assessment of Personality - Abbreviated Scale
aRefers to both LEC-IV and part 2 of LEC-5
bIncludes items 10, 11, and 16 from PCL-5
cItem 9 only
dWaitlist control group completes these measures at week 5 of the waitlist period
eWaitlist control group completes these measures at week 11 of the waitlist period
fTreatment group only
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represent their use by the individual from 1 (“Strongly
disagree”) to 7 (“Strongly agree”). This measure has
sound reliability (including test-retest reliability) [51].
Service Use and Days Out of Role Questionnaire -
modified (SUDOR) [52]. The SUDOR contains three
items that measure the impact of symptoms on daily
functioning including doctor (or other health profes-
sional) visits and days out of role or reduced functioning
due to symptom impact. Items are presented in the form
of open questions. Four additional items were included
enquiring as to medication use and additional current
treatment or activities undertaken to manage symptoms.
Credibility and Expectancy/Satisfaction Questionnaire
(CEQ) adapted from [53]. At baseline, participants will
complete two treatment expectancy questions: (1) “At this
point, how logical does the program offered to you seem?”
(0 = “Not at all logical”; 9 = “Very logical”) and (2) “At this
point, how successfully do you think this treatment will be
in reducing your PTSD symptoms?” (0 = “Not at all useful”;
4 = “Very useful”). Following the combined intervention,
participants will also rate treatment satisfaction: “How
satisfied are you with the skills that this program has
taught you to manage your PTSD?” (1 = “Not at all
satisfied”; 9 = “Very satisfied”); “How confident would
you be in recommending this treatment to a friend
who experiences similar problems?” (1 = “Not at all
confident”; 9 = “Very confident”); followed by two ques-
tions about difficulty with the program and requesting
additional feedback, which will require free text responses.
Additional measures
Life Events Checklist for DSM-IV (LEC-IV) [54]. The
LEC-IV will be used to screen for exposure to traumatic
life events. The LEC-IV assesses exposure to 16 poten-
tially traumatic events (PTEs) plus one “other” item to
capture PTEs not included in other items. It requires
respondents to code how each event was experienced
(i.e. “It happened to me; I witnessed it; I learned about
it; Not sure; Doesn’t apply to me”). It has sound test-
retest reliability and convergent validity with compar-
able measures [55].
Part 2 of the Life Events Checklist for DSM-5
(LEC-5) [56]. The LEC-5 will be used to obtain add-
itional information about reported traumatic life events
not obtained from LEC-IV, including brief description of
event, time since trauma, traumatic event frequency.
Beck Depression Inventory – Second Edition –
Question 9 (BDI-II) [57]. The BDI-II is a 21-item self-
report inventory that measures depressive symptoms.
The BDI-II possesses high internal consistency, with
alpha coefficients of 0.86 and 0.81 for psychiatric and
non-psychiatric populations, respectively [57]. Only Ques-
tion 9 from this questionnaire will be used to help deter-
mine suicidal ideation and suicide risk. Patients indicate
their level of intent to commit suicide, on a 4-point
scale (0 = “I don’t have any thoughts of killing myself”;
3 = “I would kill myself if I had the chance”).
Dissociative Experiences Scale (DES) [58]. This is a
28-item measure of dissociative symptoms. Respondents
indicate the frequency of dissociative experiences on an
11-point scale, increasing in 10-point increments from
0 % (never) to 100 % (always). This measure has strong
internal consistency and reliability over time [59].
Skills of Cognitive Behaviour Therapy for PTSD
Questionnaire. This measure has been adapted from
the Skills of Cognitive Therapy – Patient version [60]. It
is a 20-item self-report measure designed to assess pa-
tients' understanding and use of basic CBT skills in the
PTSD program. Ratings of patients' skill usage are made
on a 5-point scale (1 = “Never”; to 5 = “Always or when
needed”). Higher scores reflect greater patient subjective
skill in applying CBT therapy principles for their PTSD.
Likely Comorbid Diagnostic Status. Likely comorbid
generalised anxiety disorder (GAD), social phobia (SP),
panic disorder, agoraphobia and obsessive compulsive
disorder (OCD) status will be indexed by asking the ini-
tial enquiry question from the relevant module in the
MINI.
Standardised Assessment of Personality – Abbrevi-
ated Scale (SAPAS) [61]. The SAPAS is an 8-item
screen for DSM-IV personality disorder, with each item
requiring a Yes/No response. It is a sensitive, specific
measure of likely personality disorder [61].
Interventions
ICBT – the PTSD program
The PTSD program consists of six online lessons in the
form of a cartoon narrative that contains best practice
CBT as well as regular homework assignments and ac-
cess to supplementary resources. Lesson summaries
and skills practice homework assignments are available
for download by participants following each lesson.
Homework tasks encourage practice of the skills cov-
ered in each lesson (see Table 2). The program is com-
pleted over 10 weeks. Participants will be encouraged
to complete the program within this time and receive
automated reminders to progress. There will be a 5-day
minimum interval from completing one lesson before
the next is accessible to encourage skills practice before
continuing. However, participants can choose to log in
at any time beyond this. Participants can also choose
the duration they spend on each lesson and skills prac-
tice. Participants are encouraged to spend 3–4 hours
per week on lesson content and associated skills prac-
tice. An outline of key skills and resources covered
across the PTSD program is provided in Table 2. Lessons
are followed by skills practice assignments completed in-
dependently by patients throughout the iCBT program.
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This model has strong empirical support for the effective
treatment of depression, GAD, SP, PD with and without
agoraphobia, and mixed anxiety and depression [62], and
is already used by our online treatment service, THIS
WAY UP Clinic at St Vincent’s Hospital Sydney, Australia.
Courses for the treatment of these other disorders are cur-
rently available to patients and, to date, over 5000 patients
have completed a course.
Participant monitoring
The Clinical Trials Manager of CRUfAD and a member
of the research team will oversee participant monitoring.
Symptom severity of the target disorder and general
distress levels are measured before, during, and im-
mediately upon completing the PTSD program based
on empirically validated standardised internet-delivered
symptom measures. Participants will be sent automated
emails at the completion of each lesson to encourage skills
practice. Patient queries throughout the program are pri-
marily addressed by email contact from the clinician (AA)
or the Clinical Trials Manager (JS). If clinically indicated,
or if a patient’s K10 and/or PHQ9 or PCL-C scores deteri-
orate, the clinician makes telephone contact. If a partici-
pant misses a lesson, a member of the research team will
send an email reminder (via the Virtual Clinic system) or
will make telephone contact to remind the participant to
complete the lesson.
The treatment group will be required to complete the
iCBT program within 10 weeks to remain in the trial.
Adherence is monitored throughout the program. Once
enrolled, a participant can elect to discontinue at any
time. A participant may be withdrawn from the trial
(typically meaning course access will be closed) for the
following reasons: lack of computer and internet access;
change in prescribed medication for anxiety or depres-
sion; change in medication status of exclusion medica-
tions; suicidality or clinical risk; failure to complete
baseline questionnaires; failure to commence the PTSD
program. Lack of adherence throughout the iCBT pro-
gram is not a specified reason for participant withdrawal,
although a participant may withdraw voluntarily. Those
in the waitlist control group will be required to complete
questionnaires at weeks 1, 5 and 11 of the waitlist period
to remain in the RCT. The waitlist control group will
have access to the iCBT program immediately at the
conclusion of the waitlist period. All reasons for with-
drawal status will be documented.
To promote participant retention, participants are
reminded that data collection is an important aspect of
research and enables the research team to track their
progress and to evaluate the program. Any adverse
events will be reported to the Director of CRUfAD (GA)
and to the Human Research Ethics Committee (HREC)
of St Vincent’s Hospital, the responsible body for initiat-
ing a clinical trial audit.
Data management
All data will be collected via Virtual Clinic software and
stored on a secure Virtual Clinic server. All information
collected by the software is coded with either a partici-
pant identification number or an email address to facili-
tate data-to-patient matching. Clinical information not
obtained from the online application, including diagnos-
tic status using the MINI, is collected by interview via
telephone and stored in written format in a secure loca-
tion at CRUfAD. Any identifiable information collected
Table 2 Skills and additional resources covered over the posttraumatic stress disorder (PTSD) program by lesson
Lesson Skills Extra resources
1 • Psychoeducation on PTSD diagnosis and treatment • Managing mood
• Sleep
• Information for family and friends
2 • Psychoeducation:
o How avoidance maintains PTSD
o Fight-or-flight response
o Cognitive behavioural model of PTSD
o About cognitive behavioural therapy (CBT)
• Controlled breathing
• Progressive muscle relaxation
• Structured problem solving
3 • Link between thoughts and feelings
• Thought monitoring
• Psychoeducation for written exposure and practice of writing a trauma narrative
• Labelling emotions
4 • Psychoeducation and practice on reading the trauma narrative
• Thought challenging
• Identifying and challenging thoughts in key themes
(e.g. safety, trust)
5 • Behavioural experiments
• Situational exposure
• Continued writing and review of the trauma narrative
• Assertive communication
• Extra information for family and friends
• Attention shifting
6 • Key skills review
• Relapse prevention
None
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remains confidential, except as required by law. Only
members of the site (CRUfAD) research team will have
access to participant information and data in order
to monitor patient progress. During data analysis, re-
identifiable data (i.e. coded data) will be used. At study
completion, non-identifiable data will be written to a
password-protected database. All data will be extracted
from the Virtual Clinic servers in the form of an Excel-
compatible file to be transferred to the IBM Statistical
Package for the Social Sciences (IBM SPSS, IBM Corp.,
Armonk, NY, USA) by a member of the research team.
Participants will be informed in writing that the re-
search team plans to disseminate the trial results in
peer-reviewed scientific publications and presentations.
Participants are informed that in any such dissemin-
ation, their anonymity will be maintained.
Participants will be sent (via email) a written summary
of the results in lay terms following completion of the
trial study phase.
Statistical methods
Power calculations were informed by calculation of effect
size data from Spence et al. [20], providing a between-
group effect corresponding to Hedges’ g of 0.47. The mini-
mum sample size for each group (alpha set at 0.05, power
at 0.80) was identified as 72, but at least 10 % more will be
recruited to hedge against expected attrition. All analyses
will be conducted at conclusion of the trial period
(i.e. after all participants in the treatment group have
completed the iCBT program). Significance testing of
group differences regarding demographic data and pre-
treatment measurements will be conducted using analysis
of variance (ANOVA) and χ2 where the variables con-
sist of nominal (or categorical) data. Intent-to-treat
(ITT) mixed models using restricted maximum likeli-
hood (REML) estimation will be used to account for
missing data due to participant drop-out. Mixed models
do not assume that the last measurement is stable (the
last observation carried forward assumption) [63].
REML models are appropriate for RCTs with multiple
time points and pre-to post-only designs [64]. The as-
sumption that data are missing at random (MAR) will
be evaluated using binary logistic regression to predict
drop-out (0 = no drop-out, 1 = drop-out) and by com-
paring these two groups on baseline measures. Signifi-
cant effects will be followed up with pairwise contrasts
comparing mean pre-treatment to mean post-treatment
scores. Complete-case analyses of the primary hypoth-
eses using data from participants who complete all six
lessons of the PTSD program will also be conducted.
The effect of potential treatment moderators (e.g. time
post-trauma, number of traumatic events) will be evalu-
ated by including baseline variables of interest as a co-
variate and interaction term in separate mixed models
analyses. Analyses will be performed in IBM SPSS ver-
sion 21. Effect sizes will be calculated between groups
(Hedges’ g) and within groups (Cohen’s d, adjusting for
the repeated measures correlation) using the pooled
standard deviation and adjusted for sample size.
Mediation analyses will be used to examine the associ-
ation between change in PTSD symptoms over treat-
ment and change in each of IU and emotion regulation
in separate analyses. Tests of the indirect effects (medi-
ation) will be conducted using PROCESS [65]. This
method was chosen over the causal steps approach [66]
based on recent research advocating the use of modern
statistical approaches to quantify intervening variable
models [67]. As recommended, particularly for small
samples, estimates of indirect effects will be generated
using bootstrapping analysis see [68, 69]. Bootstrapping
is a nonparametric resampling method that generates an
estimate of the indirect effect, and does not require as-
sumptions about the shape of the sampling distribution
that underlie the Sobel test. In bootstrapping analysis,
the most stringent test of an indirect effect (mediation)
is if the 95 % bias corrected and accelerated confidence
intervals for the indirect effect do not include the value
of 0. When zero is outside of the 95 % confidence inter-
val estimate, the indirect effect is declared statistically
different from zero at p < 0.05 (two-tailed), indicating
that the effect of the independent variable on the
dependent variable is contingent upon the effect of the
proposed mediator [68]. In the current study, PROCESS
for SPSS will be used to estimate 5000 bias-corrected
bootstrap 95 % confidence intervals.
Ethics and dissemination
Staff associated with the project are aware of, and will
adhere to, the National Statement on Ethical Conduct in
Human Research (National Health and Medical Research
Council, 2007). The current trial protocol has been ap-
proved by the Human Research Ethics Committee of St
Vincent’s Hospital, Sydney, Australia. The trial is regis-
tered as ACTRN12614001213639.
All members of the research team who provide intel-
lectual input to the trial design, execution, or write-up
will be acknowledged as an author on any publications.
Discussion
The current RCT will test the efficacy of an iCBT inter-
vention for PTSD. It seeks to replicate previous efficacy
findings [20, 23] of iCBT for PTSD in a formally assessed
PTSD sample from the general population. Moreover, it
will examine the relationship between PTSD symptom
change following treatment and changes in IU and
emotion regulation. As such, results from the proposed
RCT may point to future lines of enquiry into the role
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of these constructs in the mechanism of PTSD symp-
tom change during CBT.
Notwithstanding the potential utility of the proposed
RCT, the following potential limitations are noted. The
control group in the current study is a waitlist control,
rather than an active treatment control. Therefore, it
will not be possible to eliminate a potential placebo ef-
fect. Moreover, the results will not speak to the relative
utility of iCBT for PTSD compared to an alternative
treatment approach or modality. These will be ques-
tions for future research. Further, while the trial will
examine potential change in IU and emotion regulation
ability, the iCBT program was not written to specific-
ally target either of these constructs. As such, results
will not permit definitive conclusions as to how treat-
ment components impact these constructs. The current
RCT will use DSM-IV PTSD diagnostic criteria and
associated standardised assessment instruments, as vali-
dated DSM-5 measures were not available when re-
cruitment began for the current project. While items
reflecting the three additional DSM-5 PTSD symptoms
from the PCL-5 have been included, it is important to
note that formal diagnostic and associated self-report
measures do not measure DSM-5 PTSD criteria specif-
ically. We note that while having different clinicians
conduct pre-treatment and follow-up interviews con-
trols for bias, it may introduce inter-rater variability.
Finally, history of child sexual and/or physical abuse
is not an exclusion criterion in the current study. This
approach was undertaken to maximise the generalis-
ability of the study findings, given the prevalence of
early life abuse histories in those suffering from PTSD
e.g. [5]. It is noted that emerging evidence suggests
emotion regulation skills training may be required prior
to trauma-focused treatment for survivors of child
trauma in order to optimise their potential benefit from
trauma-focused treatment e.g. [31]. Accordingly, some
national treatment guidelines suggest a period of emo-
tion regulation or stabilisation prior to trauma-focused
CBT for survivors of child abuse or other repeated/pro-
longed exposure to trauma [10, 11]. However, there is
evidence that trauma-focused treatment may have util-
ity for such people even in the absence of emotion
regulation training [38, 70, 71]. Indeed, in a treatment-
seeking sample with PTSD, Jerud et al. [32] found no
baseline differences in emotion regulation between
those with and without history of child abuse. They
further observed equivalence in improved emotion
regulation between these groups following treatment,
despite no prior emotion regulation training. Notwith-
standing, it is acknowledged that omission of emotion
regulation training may limit the potential success of
the current iCBT program for some survivors of child
trauma.
Trial status
This article was first submitted on 19 June 2015. To date,
26 participants have met eligibility requirements. The first
round of applications opened on 12 September 2014 and
the first participant was enrolled on 13 September. Data
collection aims to be complete in September 2016.
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